---
layout: post
title: "Delonix Bioworks Announces IND Clearance for DX-104, a Novel Engineered MenB OMV Vaccine Candidate, in China and Australia"
date: 2026-02-06T12:00:00+00:00
source: PR Newswire Releases
source_url: https://www.prnewswire.com/news-releases/delonix-bioworks-announces-ind-clearance-for-dx-104-a-novel-engineered-menb-omv-vaccine-candidate-in-china-and-australia-302681146.html
significance: 8.20
---

<p>SHANGHAI, Feb. 6, 2026 /PRNewswire/ -- Delonix Bioworks, a clinical-stage biotechnology company developing next-generation bacterial vaccines, recently announced that its Group B meningococcal (MenB) vaccine candidate, DX-104, has received Investigational New Drug (IND) clearance from...</p>

**Source:** [PR Newswire Releases](https://www.prnewswire.com/news-releases/delonix-bioworks-announces-ind-clearance-for-dx-104-a-novel-engineered-menb-omv-vaccine-candidate-in-china-and-australia-302681146.html)

**Published:** 2026-02-06 12:00:00 +0000

**Significance Score:** 8.20

[View original](https://www.prnewswire.com/news-releases/delonix-bioworks-announces-ind-clearance-for-dx-104-a-novel-engineered-menb-omv-vaccine-candidate-in-china-and-australia-302681146.html)
